Harbin Pharmaceutical Group Co Ltd
SSE:600664
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Price:
3.51
CNY
Market Closed
Market Cap:
¥8.8B
Relative Value
The Relative Value of one
Harbin Pharmaceutical Group Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 3.51 CNY,
Harbin Pharmaceutical Group Co Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Harbin Pharmaceutical Group Co Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Harbin Pharmaceutical Group Co Ltd Competitors
Harbin Pharmaceutical Group Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Harbin Pharmaceutical Group Co Ltd
SSE:600664
|
8.8B CNY | 0.6 | 19.7 | 10.5 | 10.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD | 14.8 | 46.7 | 31.5 | 33.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.6B USD | 6.1 | 21.4 | 14.9 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF | 4.7 | 30.4 | 12.8 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD | 4.6 | 16.3 | 10.2 | 11.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP | 5.2 | 32 | 15.3 | 22.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.2 | 8.9 | 10.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD | 2.4 | 19.4 | 7.3 | 9.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.9B USD | 2.5 | 20 | 7.1 | 9.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
